Concerns, Beliefs and Attitudes of Pharmacists About Medical Cannabis Use in Poland
Authors:
- Piotr MerksPiotr Merks
- Jameason CameronJCJameason Cameron
- Justyna KazmierczakJKJustyna Kazmierczak
- Artur BiałkowskiABArtur Białkowski
- Dariusz ŚwietlikDŚDariusz Świetlik
- Mariola BorowskaMariola Borowska
- Waldemar WierzbaWWWaldemar Wierzba
- Urszula Bołkun-SkórnickaUBUrszula Bołkun-Skórnicka
- Daniel ŚliżDŚDaniel Śliż
- Eliza BlicharskaEBEliza Blicharska
- Jarosław FedorowskiJFJarosław Fedorowski
- Regis VaillancourtRVRegis Vaillancourt
Open Access
- 22 October 2025
- journal article
- research article
- Published by MDPI AG in Healthcare
- Vol. 13 (21) , 2657
Abstract
Introduction: The global use of medical cannabis is steadily increasing. In Poland, medical cannabis was legalised in 2017; however, its use remains limited and not widely integrated into clinical practice. This study aimed to explore the attitudes, concerns, and beliefs of pharmacists and pharmacy students regarding the medical use of cannabis. Methods: A study was conducted in 2021 among 422 pharmacists and pharmacy students in Poland, primarily working in community pharmacies. Data were collected using a custom-designed questionnaire addressing beliefs, concerns, and professional experiences related to medical cannabis. Results: Nearly half of the respondents (48.9%) believe that cannabis should be used exclusively for medical purposes, while 47.6% support its use for both medical and recreational purposes following legalisation. A substantial majority (over 90%) consider cannabis effective for treating adults, with nearly 70% acknowledging its potential for treating children. Over 66% of respondents feel comfortable discussing medical cannabis with patients; however, fewer are confident in providing detailed advice about its use. The findings also highlight concerns about the long-term effects and potential legal implications of dispensing medical cannabis. Conclusions: Pharmacists and pharmacy students in Poland demonstrate openness to the medical use of cannabis and recognise its therapeutic potential. However, to enhance their ability to advise patients effectively, targeted educational initiatives are needed. These should focus on the clinical applications, safety, and long-term effects of cannabis, alongside strategies for addressing patient concerns and ensuring responsible usage.Keywords
All Related Versions
This publication has 39 references indexed in Scilit:
- Medical cannabis education among healthcare trainees: A scoping reviewComplementary Therapies in Medicine, 2021
- Knowledge, attitudes, and prescribing patterns of cannabis and cannabinoid-containing medicines among European healthcare workers: a systematic literature reviewDrug and Alcohol Dependence, 2021
- Cannabis education needs assessment among Canadian physicians-in-trainingComplementary Therapies in Medicine, 2020
- Surveys of pharmacy students and pharmacy educators regarding medical marijuanaCurrents in Pharmacy Teaching and Learning, 2019
- Impact of medication reconciliation and review and counselling, on adverse drug events and healthcare resource useInternational Journal of Clinical Pharmacy, 2018
- Availability and approval of cannabis‐based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain FederationEuropean journal of pain, 2017
- Medical marijuana and pain managementDisease-a-Month, 2016
- Medicinal Cannabis for Parkinson's Disease: Practices, Beliefs, and Attitudes Among Providers at National Parkinson Foundation Centers of ExcellenceMovement Disorders Clinical Practice, 2016
- Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhoodCochrane Database of Systematic Reviews, 2016
- Cannabinoids for Medical UseJAMA, 2015